Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Nu-Med (NUMD)

Nu-Med (NUMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Nu-Med Plus Announces Filing of U.S. Provisional Patent Application for Nitric Oxide in Aqueous Solution for Wound Care Treatment Globe NewsWire - Tue Nov 3, 2020

SALT LAKE CITY, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Nu-Med Plus, Inc . (OTCQB: NUMD ) , a medical device company which investigates and develops applications and devices for nitric oxide in the...

NUMD : 0.0591 (-8.80%)
Patent Issued for Single-Use or Short-Term Nitric Oxide Delivery Device Globe NewsWire - Tue Jul 28, 2020

SALT LAKE CITY, July 28, 2020 (GLOBE NEWSWIRE) -- Nu-Med Plus, Inc . (OTCQB: NUMD) , a medical device company which investigates and develops applications and devices for nitric oxide delivery in...

NUMD : 0.0591 (-8.80%)
Patent Issuance Allowed for Single-Use or Short-Term Nitric Oxide Delivery Device Globe NewsWire - Thu May 28, 2020

 SALT LAKE CITY, May 28, 2020 (GLOBE NEWSWIRE) -- Nu-Med Plus, Inc . (OTCQB: NUMD) , a medical device company which investigates and develops applications and devices for nitric oxide delivery...

NUMD : 0.0591 (-8.80%)

Barchart Exclusives

Is Palantir Stock Set for Another Post-Earnings Surge? Barchart - 3 minutes ago
Palantir stock has outpaced the broader markets in the last year due to stellar earnings reports and its AI platform. Is the tech stock still a good buy? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot